TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03186326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI Protocol
Description: A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Administered at 6 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered at 500 mg/m²

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered at 5 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Administered at 4 mg/Kg
Study: NCT03726021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan,Oxaliplatin, and S1
Description: Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
Study: NCT01372358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study: NCT00462644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSI sedation with etomidate/succinylcholine
Description: etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSI sedation with fentanyl/midazolam/succinylcholine
Description: 100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
Study: NCT02603133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awe
Description: This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 Good Chat
Description: This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
Study: NCT00438867

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4
Description: Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4
Description: Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group
Study: NCT03407261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations
Description: Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
Study: NCT01404611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF289
Description: Ear drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF277
Description: Ear drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF289 plus DF277
Description: Ear drops
Study: NCT03816891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vixarelimab
Description: solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vixarelimab
Description: solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vixarelimab
Description: solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vixarelimab
Description: solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vixarelimab
Description: solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection
Study: NCT02868580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
Study: NCT00550173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150 mg, orally, once daily until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg, orally, once daily until progression or unacceptable toxicity develops
Study: NCT02850328

Intervention type: OTHER
Group type: OTHER
Intervention: examination of muscle function and MVC in weightlessness
Description: MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~* Rate of force development~* Electromyographic activity~* Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~* Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~* Maximum voluntary activation capacity (%VA): %VA = (1-\[torque superimposed twitch/torque resting twitch\])\*100%.
Study: NCT01081353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin BAY1019036)
Description: One tablet of new formula Aspirin under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alka Seltzer Extra Strength
Description: One effervescent tablet under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Migraine
Description: One effervescent tablet under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Aspro
Description: One effervescent tablet under fasting conditions
Study: NCT04425993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate 5 MG
Description: All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate 5 MG
Description: All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 MG
Description: All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 100 MG
Description: All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Placebo
Description: All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sublingual Placebo
Description: All patients without contraindications should receive sublingual placebo within 5 minutes before ERCP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal placebo
Description: All patients without contraindications should receive rectal placebo within 30 min before ERCP.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rectal placebo
Description: All patients without contraindications should receive rectal placebo within 30 min before ERCP.
Study: NCT02881177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 IU
Study: NCT01784913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UV1 synthetic peptide vaccine and GM-CSF
Study: NCT01097044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
Study: NCT02603133

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 Good Chat
Description: This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 Good Chat
Description: This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
Study: NCT01148732

Intervention type: PROCEDURE
Intervention: ultrasonography
Description: a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
Study: NCT03395964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Dyna-CT guided localization
Description: We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
Study: NCT00785577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 21 mg
Description: LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks
Study: NCT03395964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative CT scan-guided localization
Description: Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
Study: NCT02949934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Study: NCT00785577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 49 mg
Description: LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 105 mg
Description: LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks
Study: NCT01212445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Description: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Description: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
Description: 13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
Study: NCT01167296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cook balloon uterine stent
Description: Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook balloon uterine stent
Description: Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
Study: NCT06656819

Intervention type: DEVICE
Intervention: Magstim Rapid2
Description: AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females

Intervention type: DEVICE
Intervention: Magstim Rapid2
Description: AIM 1: Investigate the estradiol effect on spinal circuit excitability post afferent (sensory) mediated subthreshold motor priming in young healthy women and men.~AIM 2: Characterize the Input output property of spinal circuit excitability following descending drive (motor) mediate priming in young healthy participants~AIM 3: Examine the estradiol effect on spinal circuit excitability following descending drive (motor) mediated priming in young healthy females
Study: NCT03670576

Intervention type: PROCEDURE
Intervention: Optional Bronchoscopy
Description: Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.

Intervention type: PROCEDURE
Intervention: Optional Bronchoscopy
Description: Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.

Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,

Intervention type: OTHER
Intervention: Quality of Life Questionnaires
Description: MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,

Intervention type: OTHER
Intervention: Blood Samples for Biomarkers
Description: a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.

Intervention type: OTHER
Intervention: Blood Samples for Biomarkers
Description: a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.

Intervention type: OTHER
Intervention: Home Hand Held Spirometry
Description: Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)

Intervention type: OTHER
Intervention: Home Hand Held Spirometry
Description: Patients will download an app and are given a small hand held device to record their own spirometry at home. This is blinded for the first three months of the study and then requested a week before and a week after the three follow up points (3m, 12m, 24m)
Study: NCT01607892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPT-330
Study: NCT02971592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDcure
Description: reception of real working MDcure - device that does apply the electromagnetic field

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mock Device
Description: reception of device that does not apply the electromagnetic field
Study: NCT02325713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODT-PZQ
Description: Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
Study: NCT02325713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysticide
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
Study: NCT02870946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simultaneous RRT
Description: The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
Study: NCT04210193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALK Alutard 5-grasses
Description: 0.1 mL of 10 000 SQ-U/mL (1000 SQ-U) as an intralymphatic injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALK Diluent
Description: 0.1 mL of ALK Diluent as an intralymphatic injection
Study: NCT02949934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01767415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo carmine
Description: During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.